The researchers brilliantly demonstrated, for the very first time, how to chemically transform an abundant, plant-based starting material into EBC-46.
In what can be called a major scientific breakthrough, Stanford researchers have discovered a “rapid and sustainable” way to synthetically produce a promising cancer-fighting compound, designated EBC-46, right in the lab, according to a press release published by the institution.
This was “something many people had considered impossible,” as the compound’s only currently known source is a single plant species that grows solely in a small rainforest region of Northeastern Australia.
Building A Clinically Credible Platform For Longevity Medicine — Prof. Dr. Andrea Maier MD, PhD, National University of Singapore, Centre for Healthy Longevity.
Professor Dr. Andrea B. Maier, MD, Ph.D., is the Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research, and Co-Director of the Centre for Healthy Longevity, at the National University Of Singapore (https://discovery.nus.edu.sg/19564-andrea-britta-maier).
Professor Maier is also the President of the Australia and New Zealand Society for Sarcopenia and Frailty Research, as well as Founding President of the Healthy Longevity Medicine Society — https://hlms.co/.
A Fellow of the Royal Australasian College of Physicians (FRACP), Professor Maier graduated in Medicine (MD) 2003 from the University of Lübeck (Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam (The Netherlands) in 2013 where she was the head of Geriatrics at the Vrije Universiteit Medical Center from 2012 to 2016.
A new study from the Garvan Institute of Medical Research shows how rises in core body temperature may trigger the inflammatory flares in people with a rare genetic autoinflammatory disease.
The recessive disorder, called mevalonate kinase deficiency (MKD), is caused by mutations in the gene for mevalonate kinase, an essential enzyme present in all cells in the body. Lack of this enzyme leads to a build-up of abnormal proteins, which causes cells of the immune system to malfunction and trigger inflammation.
The condition usually appears in early childhood, and patients experience regular episodes of high fever and skin rashes, ulcers, swollen lymph nodes and abdominal pain. Very severe disease also causes neurological and developmental problems and can be fatal.
Oxytocin, sometimes called the “love hormone,” may help heal broken hearts — literally. In a new study of zebrafish and human cells, scientists found that the brain-made hormone may help heart tissue regenerate after injury and, in theory, could someday be used in the treatment of heart attacks, according to the researchers.
Because the new study was conducted in fish tanks and lab dishes, however, this theoretical treatment is still far from realization.
Scientists have discovered a fluorescent protein that flouts trade-off relationships.
Scientific research institute RIKEN produced bright and photostable green fluorescent protein from Japanese jellyfish. Published in Nature Biotechnology.
Proteins that emit green light when illuminated are effective instruments for capturing images of intricate cell architecture. Such fluorescent proteins can be attached to target structures of interest, which light up when exposed to blue light.
Kuroshio Biological Research Foundation.
Published in Nature Biotechnology on August 17, the results show that the protein maintaining its brightness even when irradiated by high light has significant implications for fluorescence imaging of biological material.
Amb. Brinker is a three-time Ambassador and New York Times best-selling author who is regarded as the leader of the global breast cancer movement. Her journey began with a promise to her dying sister, Susan G. Komen, that she would do everything possible to end the shame, pain, fear, and hopelessness caused by this disease. In one generation, the organization that bears Susan’s name has changed the world.
In 2009, President Barack Obama honored Amb. Brinker with the Presidential Medal of Freedom, the nation’s highest civilian honor, for this work. The same year, she was named Goodwill Ambassador for Cancer Control for the United Nations’ World Health Organization, where she continued her mission to put cancer control at the top of the world health agenda.
In 2010, Amb. Brinker released her New York Times best-selling memoir “Promise Me — How a Sister’s Love Launched the Global Movement to End Breast Cancer” (https://www.amazon.com/gp/product/0307718123?ie=UTF8&tag=lif…07718123), an inspirational story of her transformation from bereaved sister to the undisputed leader of the ongoing international movement to end breast cancer.
From 2001–2003, Amb. Brinker served as U.S. Ambassador to the Republic of Hungary and served as U.S. Chief of Protocol from 2007–2009.
Amb. Brinker is also the host of a weekly show on Newsmax TV which features news makers, corporate leaders, and high-profile cultural thought leaders.
Microgrids are the right solution for rural and remote energy production and distribution because they are grids designed for smaller populations.
In the United States, there are at least 60,000 people who have no access to electricity. It is not a large number but poses for this population a barrier to participating in the modern world. You cannot find a job working from home without electricity and Internet access. You cannot visit your doctor virtually. You cannot use electricity to light and heat your home.
But with microgrids that can operate autonomously from the main power grid, rural and remote communities can do everything that people living in big cities can do leading to a better quality of life for those living there.
A Toronto, Canada, based company is a microgrid solutions provider. Called Clear Blue Technologies, it offers energy-as-a-service to rural and remote communities. In Nigeria, it is installing microgrids and distributed energy solutions to help rural communities to access energy and telecommunications services. Its service model manages these installations remotely at a low cost delivering clean renewable electricity while giving rural users access to the Internet. For Nigerian remote communities, it brings them into the 21st century. That’s why in March of this year, Clear Blue was awarded a contract covering 120 telecommunications sites across the country with plans in the next five years to grow that number to 1,060. Talk about levelling the playing field for these communities to give them access to clean energy and cellular phone services.
A comprehensive analysis of bacterial communities from Deception Island, an active volcano in Antarctica, highlights the potential for using heat-loving bacteria to clean up oil contamination, new research led by KAUST researchers shows.
Júnia Schultz recently joined KAUST as a postdoc working with Alexandre Rosado. She has set her sights on characterizing the microbiome of extreme terrestrial environments in Saudi Arabia, including volcanoes, deserts and geothermal sites. These extremophiles, bacteria that grow in the world’s most extreme environments, including those that love heat (thermophiles), hold immense potential for a myriad of biotechnology applications.
“Extremophiles thrive under a multitude of hostile conditions and have adapted to remain metabolically active in challenging circumstances,” says Schultz. “They exhibit versatile, diverse metabolic and physiological capabilities and often synthesize valuable bioproducts.”
A new systematic review has presented strong evidence the development of type 1 diabetes is linked to infection by enterovirus, a large group of common viruses. The findings build on a growing hypothesis linking the viruses to type 1 diabetes, with vaccines currently in development targeting the most likely viral strains.
The suggestion an enterovirus infection can trigger type 1 diabetes goes back more than 50 years, to a report published in 1969 that linked new-onset diabetes to recent infections with an enterovirus called Coxsackie B. Since then there have been a number of different studies published digging into this link, and the results have been frustratingly inconsistent.
A key 2011 study offered the first systematic review on the subject, focusing on modern molecular testing techniques (such as PCR tests). It found a clinically significant association between enterovirus infection and type 1 diabetes.
